New developments in the surgery for Parkinson's disease

Canadian Journal of Neurological Sciences

Volumn 26, Issue SUPPL. 2, 1999, Pages

  Honey, Christopher ^b   Gross, R E ^b   Lozano, Andres M ^a  

^a TORONTO WESTERN HOSPITAL   (Canada)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIPARKINSON AGENT; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR;

ARTICLE; BASAL GANGLION; BRAIN DEPTH STIMULATION; BRAIN TRANSPLANTATION; DOPAMINERGIC ACTIVITY; HUMAN; NERVE CELL NETWORK; PALLIDOTOMY; PARKINSON DISEASE; PRIORITY JOURNAL; RADIODIAGNOSIS; THALAMOTOMY; TREATMENT FAILURE; TREATMENT INDICATION; TREATMENT OUTCOME;

EID: 0032768511     PISSN: 03171671     EISSN: None     Source Type: Journal    
DOI: 10.1017/s0317167100000093     Document Type: Article

References (87)

1. Rajput AH. Frequency and cause of Parkinson's disease. Can J Neurol Sci 1992; 19(1 Suppl): 103-107.
2. Lilienfeld DE, Chan E, Ehland J, et al. Two decades of increasing mortality from Parkinson's disease among the U.S. elderly. Arch Neurol 1990; 47(7): 731-734.
3. Tasker, RR. Thalamotomy. Neurosurg Clin North Am 1990; 1: 841-864.
4. Laitinen LV, Bergenheim AT, Hariz MI. Leksell's posteroventral pallidotomy in the treatment of Parkinson's disease. J Neurosurg 1992; 76: 53-61.
5. Lozano AM, Lang AE, Galvez-Jimenez N, et al. Effect of GPi pallidotomy on motor function in Parkinson's disease. Lancet 1995; 346: 1383-1387.
6. Kishore A, Turnbull IM, Snow BJ, et al. Efficacy, stability and predictors of outcome of pallidotomy for Parkinson's disease. Six-month follow-up with additional 1-year observations. Brain 1997; 120: 729-737.
7. Kopyov O, Jacques D, Duma C, et al. Microelectrode-guided posteroventral medial radiofrequency pallidotomy for Parkinson's disease. J Neurosurg 1997; 87: 52-59.
8. Krauss JK, Desaloms JM, Lai EC, et al. Microelectrode-guided posteroventral pallidotomy for treatment of Parkinson's disease: postoperative magnetic resonance imaging analysis. J Neurosurg 1997; 87: 358-367.
9. Uitti RJ, Wharen REJ, Turk MF, et al. Unilateral pallidotomy for Parkinson's disease: comparison of outcome in younger versus elderly patients. Neurology 1997; 49: 1072-1077.
10. Samuel M, Caputo E, Brooks DJ, et al. A study of medical pallidotomy for Parkinson's disease: clinical outcome, MRI location and complications. Brain 1998; 121: 59-75.
11. Baron MS, Vitek JL, Bakay RA, et al. Treatment of advanced Parkinson's disease by posterior GPi pallidotomy: 1-year results of a pilot study. Ann Neurol 1996; 40: 355-366.
12. Lang AE, Lozano AM, Montgomery E, et al. Posteroventral medial pallidotomy in advanced Parkinson's disease. N Engl J Med 1997; 337: 1036-1042.
13. Fazzini E, Dogali M, Sterio D, Eidelberg D, Beric A. Stereotactic pallidotomy for Parkinson's disease: a long-term follow-up of unilateral pallidotomy. Neurology 1997; 48: 1273-1277.
14. Filion M, Tremblay L. Abnormal spontaneous activity of globus pallidus neurons in monkeys with MPTP-induced parkinsonism. Brain Res 1991; 547: 142-151.
15. Miller WC, Delong MR. Altered tonic activity of neurons in the globus pallidus and subthalamic nucleus in the primate MPTP model of parkinsonism. In: Carpenter MB, Jayaraman A, ed. The Basal Ganglia 2. New York: Plenum Press, 1987: 415-427.
16. Delong MR. Primate models of movement disorders of basal ganglia origin. Trends Neurosci 1990; 13: 281-285.
17. Albin RL, Young AB, Penney JB. The functional anatomy of basal ganglia disorders. Trends Neurosci 1989; 12: 366-375.
18. Grafton ST, Waters C, Sutton J, Lew MF, Couldwell W. Pallidotomy increases activity of motor association cortex in Parkinson's disease: a positron emission tomographic study. Ann Neurol 1995; 37: 776-783.
19. Samuel M, Ceballos-Baumann AO, Turjanski N, et al. Pallidotomy in Parkinson's disease increases supplementary motor area and prefrontal activation during performance of volitional movements an H2(15)O PET study. Brain 1997; 120: 1301-1313.
20. Davis KD, Taub E, Houle S, Lang AE, Dostrovsky JO, Tasker RR, et al. Globus pallidus stimulation activates the cortical motor system during alleviation of parkinsonian symptoms. Nature Medicine 1997; 3: 671-674.
21. Svennilson E, Torvik A, Lomo R, Leksell L. Treatment of Parkinsonism by stereotactic thermolesions in the pallidal region. Acta Psychiat Neurol Scand 1960; 35: 358-377.
22. Langston JW, Widner H, Goetz CG, et al. Core assessment program for intracerebral transplantations (CAPIT). Mov Disord 1992; 7: 2-13.
23. Dogali M, Fazzini E, Kolodny E, et al. Stereotactic ventral pallidotomy for Parkinson's disease. Neurology 1995; 45: 753-761.
24. Biousse V, Newman NJ, Carroll C, et al. Visual fields in patients with posterior GPi pallidotomy. Neurology 1998; 50: 258-265.
25. Sutton JP, Couldwell W, Lew MF, et al. Ventroposterior medial pallidotomy in patients with advanced Parkinson's disease . Neurosurgery 1995; 36: 1112-1116; discussion 1116-1117.
26. Guiot G, Hardy J, Albe-Fessard D. Délimitation précise des structures sous-corticales et identification de noyaux thalamiques chez l'homme par l'électrophysiologie stéréotaxique. Neurochirurgia (Stutt) 1962; 51: 1-18.
27. Benabid AL, Pollak P, Gao DM, et al. Chronic electrical stimulation of the ventralis intermedius nucleus of the thalamus as a treatment of movement disorders. J Neurosurg 1996; 84: 203-214.
28. Koller W, Pahwa R, Busenbark K, et al. High-frequency unilateral thalamic stimulation in the treatment of essential and parkinsonian tremor. Ann Neurol 1997; 42: 292-299.
29. Siegfried J, Lippitz B. Bilateral chronic electrostimulation of ventroposterolateral pallidum: a new therapeutic approach for alleviating all parkinsonian symptoms. Neurosurgery 1996; 35: 1126-1130.
30. Volkmann J, Sturm V, Weiss P, et al. Bilateral high-frequency stimulation of the internal globus pallidus in advanced Parkinson's disease. Ann Neurol 1998; 44: 953-61.
31. Gross C, Rougier A, Guehl D, et al. High-frequency stimulation of the globus pallidus intemalis in Parkinson's disease: a study of seven cases. J Neurosurg 1997; 87(4): 491-498.
32. Tronnier VM, Fogel W, Kronenbuerger M, Steinvorth S. Pallidal stimulation: an alternative to pallidotomy? J Neurosurg 1997; 87(5): 700-705.
33. Bejjani B, Damier P, Amulf I, et al. Pallidal stimulation for Parkinson's disease. Two targets? Neurology 1997; 49(6): 1564-1569.
34. Krack P, Pollak P, Limousin P, et al. Opposite motor effects of pallidal stimulation in Parkinson's disease. Ann Neurol 1998; 43(2): 180-192.
35. Galvez-Jimenex, N, Lozano A, Tasker R, et al. Pallidal stimulation in Parkinson's disease patients with a prior unilateral pallidotomy. Can J Neurol Sci 1998; 25: 300-305.
36. Limousin P, Pollak P, Benazzouz A, et al. Effect of parkinsonian signs and symptoms of bilateral subthalamic nucleus stimulation. Lancet 1995; 345: 91-95.
37. Limousin P, Krack P, Pollak P, et al. Electrical stimulation of the subthalamic nucleus in advanced Parkinson's disease. N Engl J Med 1998; 339: 1105-1111.
38. Kumar R, Lozano AM, Kim YJ, et al. Double-blind evaluation of subthalamic nucleus deep brain stimulation in advanced Parkinson's disease. Neurology 1998; 51: 850-855.
39. Kish, S.J., Shannak, K, Hornykiewicz O. Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease. N Engl J Med 1988; 318: 876-880.
40. Olanow CW, Freeman TB, Kordower JH. Neural transplantation as a therapy for Parkinson's disease. Adv Neurol 1997; 74: 249-269.
41. Mehta V, Spears J, Mendez I. Neural transplantation in Parkinson's Disease. Can J Neurol Sci 1997; 24(4): 292-301.
42. Backlund EO, Granberg PO, Hamberger B, et al. Transplantation of adrenal medullary tissue to striatum in parkinsonism. First clinical trials. J. Neurosurg 1985; 62: 169-173.
43. Lindvall O, Backlund EO, Farde L, et al. Transplantation in Parkinson's disease: two cases of adrenal medullary grafts to putamen. Ann Neurol 1987; 22: 457-468.
44. Madrazo I, Drucker-Colin R, Diaz V, et al. Open microsurgical autograft of adrenal medulla to the right caudate nucleus in Parkinson's disease: a report of two cases. N Engl J Med 1987; 316: 831-834.
45. Allen GS, Burns RS, Tulipan NB, et al. Adrenal medullary transplantation to the caudate nucleus in Parkinson's disease. Initial results in 18 patients. Arch Neurol 1989; 46: 487-491.
46. Bakay RAE. Preliminary report on adrenal medullary grafting from the American Association of Neurological Surgeons GRAFT project. Restorative Neurol Neurosci 1989; 1: 158.
47. Kelly PJ, Ahlskog JE, Van Heerden JA, et al. Adrenal medullary autograft transplantation into the striatum of Parkinson's disease. Mayo Clin Proc 1989; 64: 282-290.
48. Jiang N, Jiang C, Tang A, et al. Human foetal brain transplant trials in the treatment of Parkinsonism. Acta Acad Medicin Shangai 1987; 14(1): 77.
49. Madrazo I, Leon V, Torres C, et al. Transplantation of fetal substantia nigra and adrenal medulla to the caudate nucleus in two patients with Parkinson's disease. N Engl J Med 1988; 318: 51.
50. Lindvall O, Rehncrona S, Gustavii B, et al. Fetal dopamine-rich mesencephalon grafts in Parkinson's disease. Lancet 1988; 2: 1483-1484.
51. Lindvall O, Brundin P, Widner H, et al. Grafts of fetal dopamine neurons survive and improve motor function in Parkinson's disease. Science 1990; 247: 547.
52. Spencer DD, Robins RJ, Naftolin F, et al. Unilateral transplantation of human fetal mesencephalic tissue into the caudate nucleus of patients with Parkinson's disease. N Engl J Med 1992; 327: 1541-1548.
53. Freed CR, Breeze RE, Rosenberg NL, et al. Survival of implanted fetal dopamine cells and neurologic improvement 12 to 46 months after transplantation for Parkinson's disease. N Engl J Med 1992; 327: 1549-1555.
54. Widner H, Tetrud J, Rehncrona S, et al. Bilateral fetal mesencephalic grafting in two patients with Parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). N Engl J Med 1992; 327: 1556-1563.
55. Hitchcock ER, Kenny BG, Clough CG, et al. Stereotactic implantation of foetal mesencephalon (STIM): the UK experience. In: Dunnett SB, Richards S-J, eds. Neural Transplantation: From Molecular Basis to Clinical Applications. Progress in Brain Research. Amsterdam: Elsevier, 1990: 723-728.
56. Molina H, Quinones R, Alvarez L, et al. Transplantation of human fetal mesencephalic tissue in caudate nucleus as treatment for Parkinson's disease: the Cuban experience. In: Lindvall O, Bjorklund A, Widner H, eds. Intracerebral Transplantation in Movement Disorders. Restorative Neurology, Vol. 4, Amsterdam: Elsevier, 1991: 99-110.
57. Peschanski M, Defer G, Guyen JP, et al. Bilateral motor improvement and alteration of L-dopa effect in two patients with Parkinson's disease following intrastriatal transplantation of foetal ventral mesencephalon. Brain 1994; 117: 487-499.
58. Lopez-Lozano JJ, Bravo G, Brera B, et al. Long-term follow-up in 10 Parkinson's disease patients subjected to fetal brain grafting into a cavity in the caudate nucleus: the clinica Puerta de Hierro experience. Transplant Pro 1995; 27(1): 1395-1400.
59. Freeman TB, Olanow CW, Hauser RA, et al. Bilateral fetal nigral transplantation into the postcommissural putamen in Parkinson's disease. Ann Neurol 1995; 38(3) 379-388.
60. Freed CR, Breeze RE, Leehey MA, et al. Eight years experience with fetal neurotransplantation in patients with advanced Parkinson's disease. Soc Neurosci Abst 1996; 22(2): 481.3.
61. Savel'ev SV. Outlook for the use of nerve tissue xenotransplantation in neurosurgery. Arkhiv Patologii. 1995; 57(2): 1118.
62. Freed WJ, Morihisa JM, Spoor E, et al. Transplanted adrenal chromaffin cells in rat brain reduce lesion induced rotational behaviour. Nature 1981; 292: 351-352.
63. Wurtman RJ, Pohorecky LA, Baliga BS. Adrenocortical control of the biosynthesis of epinephrine and proteins in the adrenal medulla. Pharmacol Rev 1972; 24: 411-426.
64. Brown VJ, Dunnett SB. Comparison of adrenal and foetal nigral grafts on drug-induced rotation in rats with 6-OHDA lesions. Exp Brain Res 1989; 78: 214-218.
65. Goetz CG, Stebbins GT, Klawans HL, et al. United Parkinson Foundation Neural Transplantation Registry on adrenal medullary transplants: presurgical, and 1 and 2 year follow-up. Neurology 1991; 41: 1719-1722.
66. Date I, Shingo T, Ohmoto T, et al. Longterm enhanced chromaffin cell survival and behavioral recovery in hemiparkinsonian rats with cografted polymerencapsulated human NGFsecreting cells. Neurology 1997; 147(1): 1017.
67. Lund R, Hauscha S. Transplanted neural tissue develops connections with host rat brain. Science 1976; 193: 582-584.
68. Kordower JH, Freeman TB, Chen EY, Mufson EJ, Sanberg PR, Hauser RA, Snow B and Olanow CW. Fetal nigral grafts survive and mediate clinical benefit in a patient with Parkinson's disease. Mov Disord 1998; 13: 383-393.
69. Freeman TB, Sanberg PR, Navelt GM, et al. Influence of donor age on the survival of solid and suspension intraparenchymal human embryonic micrografts. Cell Transplant 1995; 4: 141-145.
70. Nikkhah G, Cunningham MG, Jodicke A, et al. Improved graft survival and striatal reinnervation by microtransplantation of fetal nigral cell suspensions in the rat Parkinson's model. Brain Res 1994; 633: 133-143.
71. Sloan DJ, Wood MJ, Charlton HM. The immune response to intracerebral neural grafts. Trends Neurosci 1991; 14(8): 341346.
72. Kordower JH, Freeman TB, Snow BJ, et al. Neuropathological evidence of graft survival and striatal reinnervation after the transplantation of fetal mesencephalic tissue in a patient with Parkinson's disease. N Engl J Med 1995; 332: 1118-1124.
73. Levivier M, Przedborski S, Bencsics C, et al. Intrastriatal implantation of fibroblasts genetically engineered to produce brain-derived neurotrophic factor prevents degeneration of dopaminergic neurons in a rat model of Parkinson's disease. J Neurosci 1995; 15(12): 7810-8720.
74. Tornatore C, BakerCairns B, Yadid G, et al. Expression of tyrosine hydroxylase in an immortalized human fetal astrocyte cell line; in vitro characterization and engraftment into the rodent striatum. Cell Transplant 1996; 5(2): 145-163.
75. Maysinger D, Piccardo P, Cuello AC. Microencapsulation and the grafting of genetically transformed cells as therapeutic strategies to rescue degenerating neurons of the CNS. Rev Neurosci 1995; 6(1): 1533.
76. Date I, Miyoshi Y, Ono T, et al. Preliminary report of polymerencapsulated dopamine-secreting cell grafting into the brain. Cell Transplant 1996; 5; (5 Suppl 1): S1719.
77. Whittemore SR, Eaton MJ, Onifer SM. Gene therapy and the use of stem cells for central nervous system regeneration. Adv Neurol 1997; 72: 113-119.
78. Freese A, Stern M, Kaplitt MG, et al. Prospects for gene therapy in Parkinson's disease. Mov Disord 1996; 11(5): 469-488.
79. Freeman TB. From transplants to gene therapy for Parkinson's disease. Exp Neurol 1997; 144(1): 47-50.
80. Horellou P, Mallet J. Gene therapy for Parkinson's disease. Mol Neurobiol 1997; 15(2): 241-256.
81. Galpern WR, Burns LH, Deacon TW, et al. Xenotransplantation of porcine fetal ventral mesencephalon in a rat model of Parkinson's disease: functional recovery and graft morphology. Exp Neurol 1996; 140(1): 113.
82. Dinsmore JH, Pakzaban P, Deacon TW, et al. Survival of transplanted porcine neural cells treated with F(ab')2 antibody fragments directed against donor MHC class in a rodent model. Transplantation Proc 1996; 28(2): 817-818.
83. Oppenheim RW. The neurotrophic theory and naturally occuring motorneuron death. Trends Neurosci 1989; 12: 252-255.
84. Lin LH, Doherty DH, Lile JD, et al. GDNF: a glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons. Science 1993; 260: 1130-1132.
85. Hudson J, Granholm AC, Gerhardt GA, et al. Glial cell line-derived neurotrophic factor augments midbrain dopaminergic circuits in vivo. Brain Res Bulletin 1995; 36(5): 425-432.
86. Shults CW, Kimber T, Martin D. Intrastriatal injection of GDNF attenuates the effects of 6-hydroxydopamine. Neuroreport 1996; 7(2): 627-631.
87. Gash DM, Zhang Z, Ovadia A, et al. Functional recovery in parkinsonian monkeys treated with GDNF. Nature 1996; 380(6571): 252-255.